Mark W Riemen is a notable inventor based in Doylestown, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of modified proteins for therapeutic applications. With a total of 7 patents to his name, Riemen's work has had a considerable impact on medical research and treatment options.

Latest Patents

One of Riemen's latest patents involves the modification of pseudomonas exotoxin PE.sub.40. This modification includes deleting or substituting one or more cysteine residues, resulting in a protein that can be incorporated into a fusion protein with TGF.alpha. The resulting fusion protein exhibits altered biological activities compared to unmodified TGF.alpha.-PE.sub.40, including decreased cell killing activity and increased receptor-binding activity. Another patent focuses on the same modified pseudomonas exotoxin PE.sub.40, highlighting its potential for hybridization with TGF.alpha. to achieve similar altered biological activities.

Career Highlights

Mark W Riemen is currently associated with Merck & Company, Inc., where he continues to innovate and contribute to the field of biotechnology. His work at Merck has allowed him to collaborate with leading experts and researchers in the industry, further enhancing his contributions to medical science.

Collaborations

Some of Riemen's notable coworkers include Allen I Oliff and David C Heimbrook. Their collaborative efforts have played a crucial role in advancing research and development in their respective fields.

Conclusion

Mark W Riemen's innovative work in modifying pseudomonas exotoxin PE.sub.40 showcases his dedication to advancing medical research. His contributions have the potential to lead to significant improvements in therapeutic applications, making him a key figure in the biotechnology industry.